Mr. Matin was previously the Business Unit Director for Boston Scientific Corporation's Cardiac Rhythm Management operations in China. Prior to that, he served in several executive and management positions with Guidant Corporation, including General Manager of Southeast Asia and Pakistan, Clinical Sales Representative in the U.S., and Group Leader for Vascular Intervention Manufacturing Engineering in Europe. Mr. Matin has a Bachelor of Science degree in Mechanical Engineering from the University of California, Berkeley, and a Master of Business Administration degree from Harvard Business School.

"Shar Matin's broad base of experience, which includes sales, manufacturing, and operations management, is the perfect background for leading our European business," said John G. Schulte, Spectranetics' president and chief executive officer. "We believe there is an outstanding opportunity to grow our business in Europe, and I'm delighted to have an executive with a track record of success like Shar Matin driving our initiatives there."

About Spectranetics

Founded in 1984, Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in multiple, minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The Company's disposable catheters use high-energy "cool" ultraviolet light to vaporize arterial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads. For more information visit www.spectranetics.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.

Spectranetics and CVX-300 are registered trademarks of The Spectranetics Corporation.

COMPANY CONTACT:
Spectranetics Corporation
Guy Childs, Chief Financial Officer
(719) 633-8333
www.spectranetics.com

INVESTOR & MEDIA CONTACTS:
Lippert/Heilshorn & Associates, Inc.
Bruce Voss
Don Markley
(310) 691-7100
www.lhai.com

SOURCE Spectranetics Corporation

Guy Childs, Chief Financial Officer of Spectranetics Corporation, +1-719-633-8333; or Investors & Media, Don Markley or Bruce Voss, both of Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, for Spectranetics Corporation

http://www.spectranetics.com